Top Industry Leaders in the Migraine Brainstem Aura Market
Latest Migraine with Brainstem Aura Companies Update:
Biogen acquires Alder BioPharmaceuticals: This move expands Biogen's neurology portfolio and grants them access to Alder's rimegepant oral medication for preventing migraine, which could potentially benefit MBA patients.
Eli Lilly partners with Cohero Health to develop digital therapeutics for migraine: This collaboration aims to leverage Cohero's expertise in behavioral health solutions to create digital tools for managing and preventing migraine attacks, including those with brainstem aura.
Botox receives FDA approval for preventive treatment of chronic migraine: While not specific to MBA, this broader approval for chronic migraine could indirectly benefit some patients who experience migraine with brainstem aura as part of their chronic migraine condition
List of Migraine with Brainstem Aura Key companies in the market
- Allergen Plc,
- Merck & Co., Inc.,
- Pfizer, Inc.,
- GlaxoSmithKline Plc,
- Abbott Laboratories,
- AstraZeneca,
- Eisai Co., Ltd.,
- Endo International Plc,
- Impax Laboratories,
- Eli Lily and Company,
- Johnson & Johnson